Skip to main content
SpringerLink
Log in

Combined Modality Therapy in Locally Advanced Breast Cancer

  • Chapter
Chemoradiation in Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 125 Accesses

Abstract

The management of locally advanced breast cancer requires the integration of surgery, chemotherapy, and radiation therapy. This chapter summarizes the existing experience and addresses some of the remaining issues in combined modality therapy of locally advanced and inflammatory breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schaake-Koning C, van der Linden EH, Hart G, Engelsman E. Adjuvant chemo-and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiat Oncol Biol Phys 1985; 11: 1759–1763.

    Article  PubMed  CAS  Google Scholar 

  2. Rubens RD, Bartelink H, Engelsman E, et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792). Eur J Cancer Clin Oncol 1989; 25: 667–678.

    Article  PubMed  CAS  Google Scholar 

  3. Grohn P, Heinonen E, Klefstrom P, Tarkkanen J. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 1984; 54: 670–674.

    Article  PubMed  CAS  Google Scholar 

  4. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310–1317.

    PubMed  CAS  Google Scholar 

  5. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III nonsmall-cell lung cancer. J Clin Oncol 1999; 17: 2692–2699.

    PubMed  CAS  Google Scholar 

  6. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606–1613.

    PubMed  CAS  Google Scholar 

  7. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407–1412.

    PubMed  CAS  Google Scholar 

  8. Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays. Int J Radiat Oncol, Biol, Phy 1982; 8: 1923–1933.

    CAS  Google Scholar 

  9. Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA- directed effects. Int J Radiat Oncol Biol Phys 1994; 29: 519–523.

    Article  PubMed  CAS  Google Scholar 

  10. Janjan NA, Crane CN, Feig BW, et al. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2000; 47: 713–718.

    Article  PubMed  CAS  Google Scholar 

  11. Cafiero F, Gipponi M, Peressini A, Bertoglio S, Lionetto R. Preliminary analysis of a randomized clinical trial of adjuvant postoperative RT vs. postoperative RT plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer. J Surg Oncol 2000; 75: 80–88.

    Article  PubMed  CAS  Google Scholar 

  12. Jabboury K, Holmes FA, Hortobagyi G. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 1989; 64: 793–797.

    Article  PubMed  CAS  Google Scholar 

  13. Formenti SC, Uziely B, Dunnington G, et al. Continuous infusion (ci) 5-fluorouracil (FU) with radiation in locally advanced breast cancer: clinicopathological and biological correlates (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1995; 14: A358.

    Google Scholar 

  14. Formenti SC, Dunnington G, Uzieli B, et al. Original p.53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol, Biol, Physics 1997; 39: 1059–1068.

    CAS  Google Scholar 

  15. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460–469.

    PubMed  CAS  Google Scholar 

  16. Merajver SD, Weber BL, Cody R, et al. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol 1997; 15: 2873–2881.

    PubMed  CAS  Google Scholar 

  17. Morrell LE, Lee YJ, Hurley J, et al. A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer 1998; 82: 503–511.

    Article  PubMed  CAS  Google Scholar 

  18. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547–552.

    PubMed  CAS  Google Scholar 

  19. Karlsson YA, Malmstrom PO, Hatschek T, et al. Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications. Cancer 1998; 83: 936–947.

    Article  PubMed  CAS  Google Scholar 

  20. Zambetti M, Oriana S, Quattrone P, et al. Combined sequential approach in locally advanced breast cancer. Annals Oncol 1999; 10: 305–310.

    Article  CAS  Google Scholar 

  21. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2: 72–79.

    Article  PubMed  CAS  Google Scholar 

  22. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1995; 1: 506–526.

    Google Scholar 

  23. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50–56.

    PubMed  CAS  Google Scholar 

  24. Milas L, Hunter NR, Kurdoglu B, et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 1995; 35: 297–303.

    Article  PubMed  CAS  Google Scholar 

  25. Symmans W, Volm M, Shapiro R, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000; 6: 4610–4617.

    PubMed  CAS  Google Scholar 

  26. Formenti SC, Symmans WF, Volm M, et al. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol 1999; 9: 34–42.

    PubMed  CAS  Google Scholar 

  27. Horwitz S, Zambetti M, Oriana S, et al. Taxol: Mechanisms of action and resistance. JNCI Monographs 1993; 15: 55–61.

    Google Scholar 

  28. Kavallaris M, Kuo DYS, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100: 1282–1293.

    Article  PubMed  CAS  Google Scholar 

  29. Nguyen HL, Chari S, Gruber D, Lue CM, Chapin SJ, Bulinski JC. Overexpression of full-or partial-length MAP4 stabilizes microtubules and alters cell growth. J Cell Sci 1997; 110: 281–294.

    PubMed  CAS  Google Scholar 

  30. Zhang C. Genetic susceptibility to microtubule-active cancer chemotherapeutic drugs: p53 action and the role of MAP4. Proceedings of AACR 1998; 1308.

    Google Scholar 

  31. Haldar S, Chintapalli J, Croce CM. Taxol induces Bc1–2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253–1255.

    PubMed  CAS  Google Scholar 

  32. Montgomery RB, Guzman J, O’Rourke DM, Stahl WL. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 2000; 275:17, 358–17, 363.

    Google Scholar 

  33. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/ neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999; 59: 1347–1355.

    PubMed  CAS  Google Scholar 

  34. Formenti S, Low HER 2/NEU Gene Expression is Associated with Pathological Response to Primary Paclitaxel and Radiation in Locally Advanced Cancer (LABC). Proceedings of ASTRO 2000; 63.

    Google Scholar 

  35. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93–100.

    PubMed  CAS  Google Scholar 

  36. Formenti SC, Cohen D, Tsao-Wei DD, et al. Clinical Course of Locally Advanced Breast Cancer (LABC) Patients with pathological response to primary concurrent 5-fluorouracil and radiation (FU/ RT). Im J Radiat Oncol Biol Phys 2001; 51: 195–196 (abstract 1039).

    Article  Google Scholar 

  37. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin NAm 1995; 4: 715–734.

    CAS  Google Scholar 

  38. Maloisel F, Dufour P, Bergerat JP, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 1990; 65: 851–855.

    Article  PubMed  CAS  Google Scholar 

  39. Viens P, Penault-Llorca F, Jacquemier J, et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant 1998; 21: 249–254.

    Article  PubMed  CAS  Google Scholar 

  40. Cagnoni PJ, Nieto Y, Shpall EJ, et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 1998; 16: 1661–1668.

    PubMed  CAS  Google Scholar 

  41. Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer 1993; 67: 594–601.

    Article  PubMed  CAS  Google Scholar 

  42. Fields JN, Perez CA, Kuske RR, Fineberg BB, Bartlett N. Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys 1989; 17: 249–255.

    Article  PubMed  CAS  Google Scholar 

  43. Thorns WW Jr, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 1989; 17: 739–745.

    Article  Google Scholar 

  44. Rouesse J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986; 4: 1765–1771.

    PubMed  CAS  Google Scholar 

  45. Thomas E, Buzdar A, Hortobagyi G, et al. Long-Term Follow Up of Stage III Breast Cancer-Combined Modality Treatment with Anthracycline Containing Chemotherapy (CT): The MD Anderson Experience (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1999; 18: A284.

    Google Scholar 

  46. Honkoop AH, Luykx-de Bakker SA, Hoekman K, et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist 1999; 4: 106–111.

    PubMed  CAS  Google Scholar 

  47. Dhingra K, Esparza-Guerra L, Valero V, et al. A Phase III Randomized Trial of Dose-Intensive, Neoadjuvant 5FU, Doxorubicin, Cyclophosphamide (FAC) with G-CSF (filgrastim) in Locally Advanced Breast Cancer (LABC)-Efficacy and Safety Data (Meeting abstract). Proc Anna Meet Am Soc Clin Oncol 1999; 18: A278.

    Google Scholar 

  48. Eltahir A, Heys SD, Hutcheon AW, et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 1998; 175: 127–132.

    Article  PubMed  CAS  Google Scholar 

  49. De Matteis A, Montella M, Iannuzzo M, et al. Multimodal treatment strategy for locally advanced breast cancer. J Chemother 1998; 10: 476–483.

    PubMed  Google Scholar 

  50. Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73: 362–369.

    Article  PubMed  CAS  Google Scholar 

  51. Ayash U, Elias A, Ibrahim J, et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 1998; 16: 1000–1007.

    PubMed  CAS  Google Scholar 

  52. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998; 176: 502–509.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Silvia C. Formenti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Volm MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Hak Choy MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Formenti, S.C., Volm, M. (2003). Combined Modality Therapy in Locally Advanced Breast Cancer. In: Choy, H. (eds) Chemoradiation in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-325-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-325-5_12

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-313-8

  • Online ISBN: 978-1-59259-325-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation